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Abstract

Author Manuscript

Despite a high prevalence of sleep disruption among hematopoietic cell transplant (HCT)
recipients, relatively little research has investigated its relationships with modifiable cognitive or
behavioral factors or used actigraphy to characterize sleep disruption in this population.
Autologous HCT recipients who were 6 to 18 months post-transplant completed self-report
measures of cancer-related distress, fear of cancer recurrence, dysfunctional sleep cognitions, and
inhibitory sleep behaviors upon enrollment. Patients then wore an actigraph for seven days and
completed a self-report measure of sleep disruption on day seven of the study. Among the 84
participants (age M=60, 45% female), 41% reported clinically-relevant sleep disruption.
Examination of actigraph data confirmed that, on average, sleep was disrupted (wake after sleep
onset M=66 minutes) and sleep efficiency was less than recommended (sleep efficiency M=78%).
Cancer-related distress, fear of recurrence, dysfunctional sleep cognitions, and inhibitory sleep
behaviors were related to self-reported sleep disruption (p’s < .05) but not objective sleep indices.
Results suggest that many HCT recipients experience sleep disruption after transplant. Cancerrelated distress, fear of recurrence, dysfunctional sleep cognitions, and maladaptive sleep
behaviors are related to self-reported sleep disruption and should be considered targets for
cognitive behavioral intervention in this population.
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Introduction
Sleep disruption is one of the most common quality of life concerns following hematopoietic
cell transplantation (HCT),1,2 with as many as 77% of patients reporting sleep difficulties.3
Sleep disruption encompasses a variety of sleep complaints including insomnia, which is
characterized by problems falling or staying asleep, waking earlier than planned, and/or
experiencing non-restorative sleep.4 Faulhaber and colleagues found that 23% of HCT
recipients between 1 and 10 years post-transplant reported problems with insomnia.5
Moreover, it has been consistently demonstrated that sleep quality is worse among HCT
recipients in the post-transplant period compared to healthy individuals.6–13

Author Manuscript

Most evidence regarding sleep disruption among HCT recipients comes from single-item
measures incorporated into quality of life questionnaires. These studies may fail to capture
the complexity of sleep issues. Additional methodological limitations include small sample
sizes and assessment of sleep disruption utilizing mixed samples of autologous and
allogeneic transplant recipients. Autologous transplant recipients may experience different
rates of sleep disruption than allogeneic recipients, who often receive steroids to treat
GVHD, which may interfere with sleep. 26,27 Existing literature is also characterized by
exclusive reliance upon self-reports to measure sleep problems with no use of currently
available actigraph technology. Actigraphy, which involves the objective measurement of
movement by means of an accelerometer14 has been successfully used to measure sleep/
wake patterns in cancer patients15–19 and correlates at a rate of about 90% agreement with
polysomnography.20 Use of actigraphy is important to provide a more complete picture of
sleep disruption among HCT patients.
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Given the burden of sleep disruption among HCT patients, it is important to understand risk
factors. Prior studies have often generally focused on demographic and clinical predictors.21
For example, older age22,23 and female sex13,24,25 have been reported to be associated with
worse sleep quality among HCT recipients. However, data are lacking regarding potentially
modifiable risk factors. Cancer-related distress and fear of cancer recurrence have been
associated with sleep disruption in breast cancer patients.28,29 In addition, evidence suggests
that dysfunctional sleep-related thoughts and behaviors contribute to the perpetuation of
insomnia symptoms in cancer patients and individuals without cancer.30–33 However,
relationships between cognitive-behavioral factors and sleep disruption have not been
investigated among HCT recipients.
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The goals of the current study were to characterize the prevalence and severity of sleep
disruption following autologous HCT measured subjectively and objectively as well as to
examine the contribution of modifiable risk factors (i.e., cancer-related distress, fear of
cancer recurrence, and dysfunctional sleep related thoughts and behaviors).

Materials and Methods
Participants
Participants were recruited from the Moffitt Cancer Center. Eligible participants: 1) were
diagnosed with a hematologic malignancy, 2) were treated with autologous HCT 6 – 18
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months prior to study enrollment, 3) were ≥18 years of age, 4) had no history of other
cancers other than non-melanoma skin cancer, 5) had no evidence of disease progression at
the time of study enrollment, 6) were able to speak and read English, and 7) were able to
provide informed consent. The 6 to 18 month timeframe was chosen based on previous
literature suggesting sleep quality remains relatively stable following day 100 posttransplant44,45. Data were collected from May 2015 to February 2016.
Procedures

Author Manuscript

The study was approved by the University of South Florida Institutional Review Board.
Eligibility was determined via medical record review in consultation with physicians and
clinical staff. Patients were recruited during a scheduled outpatient appointment during
which they completed an initial questionnaire assessing demographics, cancer-specific
factors, and cognitive and behavioral factors related to sleep disruption. They then wore the
actigraph for seven consecutive 24-hour periods and completed a sleep log used to aid in
determination of bed and rise times. At the end of the monitoring period, participants
completed a self-report measure of sleep keyed to the previous seven days.
Measures
Demographic and Clinical Characteristics: Participants completed a standardized selfreport form assessing age, sex, race, ethnicity, education, income, marital status, and
employment status, a self-report version of the Eastern Cooperative Oncology Group
(ECOG) performance status scale, and provided information on recent use of medications to
promote sleep. Relevant clinical information (i.e., diagnosis, time since transplant) was
collected via medical record review.
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Cancer-related Distress: The intrusion subscale of the Impact of Events Scale (IES)34 is a
7-item self-report measure assessing psychological distress during the past week. The
measure was keyed to “cancer and its treatment.” Higher scores indicate greater distress.
Fear of Cancer Recurrence: The Fear of Cancer Recurrence Inventory (FCRI) is a 42-item
self-report measure assessing fear or worry that cancer will return or progress.35 Higher
scores indicate greater fear of recurrence.

Author Manuscript

Dysfunctional Beliefs and Attitudes About Sleep: The Dysfunctional Beliefs and
Attitudes about Sleep scale (DBAS-16) is a 16-item, self-report measure assessing faulty
beliefs, worries, and attentional biases surrounding sleep-related cognitions (e.g., After a
poor night’s sleep, I know it will interfere with my activities the next day).36 Higher scores
indicate more dysfunctional beliefs and attitudes about sleep.
Sleep Effort: The Glasgow Sleep Effort Scale (GSES) is a 7-item self-report measure
assessing the extent to which individuals engage in effortful attempts to sleep (e.g., I put too
much effort into sleeping when it should come naturally).37 Higher scores indicate greater
sleep effort.
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Sleep Hygiene: The Sleep Hygiene Index (SHI) is a 13-item self-report measure assessing
the extent to which individuals practice healthy behaviors that facilitate sleep and avoid
behaviors that interfere with sleep (e.g., I go to bed at different times from day to day).38
Higher scores indicate worse sleep hygiene.
Self-reported Sleep Disruption: The Insomnia Severity Index (ISI) is a 7-item self-report
measure assessing the nature, severity, and impact of insomnia during the past week.39
Higher scores indicate worse insomnia symptoms. Total ISI scores are interpreted as
follows: 0–7 indicates no clinically significant insomnia, 8–14 indicates subthreshold
insomnia, 15–21 indicates clinical insomnia (moderate severity), and 22–28 indicates
clinical insomnia (severe).39
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Objective Sleep Disruption: The Philips Respironics Actiwatch-Score (Philips Healthcare,
Andover, MA) was used to objectively quantify sleep patterns. Participants were asked to
wear the actigraph on their non-dominant wrist continuously for a seven-day period.
Consistent with published recommendations41, sleep variables examined included sleep
efficiency (i.e., percentage of time spent sleeping in relation to time spent in bed), sleep
onset latency (SOL, i.e., amount of time taken to fall asleep), wake after sleep onset (WASO,
i.e., minutes awake after an extended period of sleep), and total sleep time (TST, i.e., time
spent asleep at night). Sleep efficiency served as the primary objective outcome of interest.
We used sleep efficiency categories from the Pittsburgh Sleep Quality Index42 to categorize
sleep efficiency in this population.
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Statistical Analyses—Data were first examined for normality of distribution and outliers.
Mean imputation was used to address sporadic missing items. Multiple imputation was used
for scales for which all items were missing (SAS Institute Inc, 2011);43 the number of
imputed data points never exceeded three participants per scale. Descriptive statistics were
used to characterize the prevalence and severity of sleep disruption and the sleep indices that
could be derived. Pearson correlation coefficients were used to examine relationships
between sleep outcomes and demographic and clinical factors and the hypothesized cancerspecific, cognitive, and behavioral risk factors.
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Finally, a series of multivariable regression models were conducted to explore the variance
in sleep disruption accounted for by demographic and clinical factors, cancer-specific
factors, and cognitive and behavioral factors. Demographic and clinical factors significantly
correlated with the outcome variables were entered into the first of these models. Cancerspecific factors were then added to the second models. Finally, cognitive and behavioral
factors were added to the final models. Data analyses were performed using SAS Version 9.4
(Cary, NC). A p value < .05 (two-tailed) was considered statistically significant.

Results
Recruitment and Patient Characteristics
Supplemental Figure 1 depicts participant flow. Demographic and clinical characteristics of
the sample (n=84) are shown in Table 1. Patients were an average of 60 years of age. The
majority were male (55%), non-Hispanic (94%), white (87%), had completed some college
Bone Marrow Transplant. Author manuscript; available in PMC 2018 June 21.
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(64%), and were diagnosed with multiple myeloma (69%). At the time of participation,
patients were an average of 350 days post-transplant and the majority reported they were not
currently taking sleeping medication (61%).
Prevalence and Severity of Sleep Disruption and Hypothesized Risk Factors
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The mean ISI score was 7.07 (SD=5.58); 41% of the sample reported clinically-significant
sleep disruption (ISI total scores ≥ 8), with 30% meeting subthreshold insomnia, 10%
moderate severity, and 1% severe insomnia. Actigraphy data indicated that, on average,
patients took 20 minutes to fall asleep at night, spent approximately one hour awake after
initially falling asleep, and spent 6.5 hours asleep. Overall, patients had a mean sleep
efficiency of 78%, with 21% meeting sleep efficiency ratings of ≥85%, 50% in the 75 to
84% range, 19% in the 65 to 74% range, and 10% <65%. HCT recipients’ subjective reports
of sleep disruption were associated with objectively calculated total sleep time, p = .04;
however, subjectively reported sleep was not associated with any of the other objective
measure of sleep disruption, all p’s > .05.
On average, patients reported relatively low levels of intrusion (M = 10.53, SD = 8.21) and
functional impairment from fear of cancer progression (M = 5.82, SD = 6.28) and moderate
fear of cancer progression (M = 15.67, SD = 8.04). The average patient endorsed some
dysfunctional beliefs and attitudes about sleep (M = 3.87, SD = 2.07) as well as sleep effort
(M = 3.52, SD = 2.86) and relatively low levels of unhealthy sleep habits (M = 26.44, SD =
5.39).
Risk Factors for Sleep Disruption
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As shown in Table 2, subjective sleep disruption was not significantly associated with any
demographic and clinical variables (p values > .05). Objective sleep disruption was
significantly associated with age, ethnicity, and time since transplant. Specifically, younger
patients and Hispanic patients demonstrated longer sleep onset latency (p values < .05).
Hispanic patients also demonstrated worse sleep efficiency compared to non-Hispanic
patients (p = .05). In addition, patients who had been transplanted more recently
demonstrated shorter total sleep time (p < .05).
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Relationships of cancer-specific risk factors with subjective and objective sleep disruption
appear in Table 2. Intrusive psychological distress as measured by the IES and severity and
functional impairment related to fear of cancer progression as measured by the FCRI were
related to subjective sleep disruption (p values < .05). Functional impairments resulting from
fear of cancer recurrence was related to longer sleep onset latency (p = .02). None of the
other cancer-specific risk factors were significantly related with any of the objective indices
of sleep disruption (p values > .05).
Relationships of cognitive and behavioral risk factors with subjective and objective sleep
disruption appear in Table 2. Dysfunctional beliefs and attitudes about sleep as measured by
the DBAS, sleep effort as measured by the GSES, and sleep hygiene as measured by the SHI
were related to subjective sleep disruption (p values < .05). None of the cognitive and
behavioral risk factors were related with any of the objective indices of sleep disruption (p
values > .05).
Bone Marrow Transplant. Author manuscript; available in PMC 2018 June 21.
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Table 3 shows results from the multivariable models with subjective sleep disruption as the
outcome. No sociodemographic and clinical factors were related to subjective sleep
disruption, therefore none were included. The block of variables including IES intrusion,
FCRI severity, and FCRI functional impairment scores accounted for 8% of the variance in
subjective sleep, with FCRI impairment being the only statistically significant predictor.
Patients reporting greater functional impairment also reported worse subjective sleep
disruption. When DBAS, GSES, and SHI were added to the model, all factors together
accounted for 37% of the variance in subjective sleep (ΔR2 = 29%, F(6, 74) = 5.68, p < .
001), with GSES being the only statistically significant predictor. Patients reporting greater
sleep effort reported worse subjective sleep disruption.
Multivariable Models with Risk Factors for Objective Sleep Disruption
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Table 4 shows results from the multivariable models with objective sleep disruption as the
outcome. In the first model, age and ethnicity were entered and accounted for 12% of the
variance in sleep onset latency, with younger patients and Hispanic patients taking longer to
fall asleep. In the second model, IES intrusion, FCRI severity, and FCRI functional
impairment were added and accounted for an additional 9% of the variance in sleep onset
latency; however, none of the added factors were statistically significant. In the final
combined model, DBAS, GSES, and SHI were entered in addition to the other factors. All
factors entered together accounted for 23% of variance in sleep onset latency, but ethnicity
remained as the only statistically significant predictor.

Discussion
Author Manuscript

The present study characterized sleep disruption measured subjectively and objectively and
examined potential demographic, clinical, cancer-specific, cognitive, and behavioral risk
factors for sleep disruption among autologous HCT recipients between 6 and 18 months
post-transplant. A total of 41% of patients reported clinically relevant sleep disruption.
While estimates of the prevalence of sleep disruption in HCT patients vary widely, results
from the present study are generally in line with estimates in the survivorship period
following HCT.5,22,26,44,45 Actigraphy revealed that patients spent over an hour awake after
falling asleep and spent an average of 6.5 hours asleep at night. Patients took approximately
20 minutes to fall asleep at night and average sleep efficiency was 78%, which is below the
recommended 85% often used as a cut point to indicate healthy sleep.46 Taken together,
these descriptive data indicate that a large proportion of autologous HCT patients experience
poor sleep.
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In univariate analyses, cancer-specific, cognitive, and behavioral factors were associated
with subjective but not objective sleep disruption. In multivariable models, only sleep effort
as measured by the GSES emerged as a significant predictor of subjective sleep disruption.
This pattern of results indicates that it may be patients’ distorted cognitions, more than
cancer-related distress or unhealthy sleep habits that are the primary drivers of their selfreported sleep disruption. If this is the case, it may be particularly important to change
distorted cognitions in addressing HCT patients’ sleep complaints. In multivariable models
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with objectively measured sleep onset latency as the outcome, demographic factors
demonstrated the strongest relationship, with Hispanic ethnicity emerging as the only
significant predictor of worse sleep onset latency. Randomized controlled trials of
psychologically-based sleep interventions with cancer patients have generally demonstrated
a reduction in objectively measured sleep disruption following intervention delivery.46–48
However, these studies mostly recruited patients with breast cancer and therefore may not
generalize to the autologous HCT setting.
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The lack of relationship found between subjectively and objectively measured sleep is
consistent with previous research and suggests that these two methods of sleep measurement
assess different aspects of sleep. The finding that self-reported cognitive and behavioral
factors were not associated with objective sleep in the present study raises the question of
whether sleep interventions that target these mechanisms (e.g., CBT-I, MBSR) improve
objective indices of sleep among autologous transplant recipients or may improve objective
sleep through other mechanisms not assessed in this study (e.g., self-efficacy for managing
sleep disturbance). Nevertheless, cancer-specific, cognitive, and behavioral factors were
related to subjective reports of sleep, which is the more clinically-relevant outcome. No
studies have been conducted of CBT-I or MBSR for sleep in HCT recipients. Because CBT-I
and MBSR are evidenced-based treatments to improve sleep and, unlike medication, do not
have the potential for side effects or dependency, they should still be considered for
autologous HCT patients who report significant sleep disturbance.
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Study limitations include the cross-sectional assessment of sleep, which prevented
examination of how relationships between cancer-related, cognitive, and behavioral factors
and sleep disruption change over time. Future research should examine changes in objective
sleep longitudinally. The study was also limited by the lack of ethnic and racial diversity of
its participants, which limits generalizability to other groups. In addition, the majority of the
sample was diagnosed with multiple myeloma. Because autologous transplant is not curative
for this disease cancer-related distress may be higher in these patients than in those with
other diagnoses. Finally, other potential contributing factors (e.g., pain) were not assessed.
Despite these limitations, the present study adds to a strong foundation of prior literature
examining perpetuating factors of insomnia. Moreover, this study investigated not only
subjective but also objective sleep disruption among a homogenous group of autologous
transplant recipients, which to the best of our knowledge has not been done in HCT recipient
survivorship.
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In summary, patients reporting subjective sleep disruption should be referred for
pharmacological or psychological sleep intervention after ruling out other concomitant
medical conditions. Results from the present study suggest that a large proportion of
autologous HCT recipients have dysfunctional cognitions about sleep and maladaptive sleep
habits, both of which are targets for sleep interventions such as CBT-I. Moreover, CBT-I is a
recommended treatment for clinical sleep issues in cancer patients.30,46,47 MBSR is another
treatment with demonstrated efficacy among cancer patients.49,50 Future research should
investigate the efficacy of interventions such as CBT-I and MBSR with autologous HCT
recipients, particularly for those patients who report moderate to severe sleep disruption.
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Table 1

Author Manuscript

Demographic and Medical Characteristics (N = 84)
Characteristic
Age, years

M

59.67

SD

11.91

Gender, No. (%)
Male

46 (54.8)

Female

38 (45.2)

Ethnicity, No. (%)
Not Hispanic

79 (94.0)

Hispanic

4 (4.8)

Missing

1 (1.2)

Author Manuscript

Race, No. (%)
White

73 (86.9)

Nonwhite

11 (13.1)

Marital Status, No. (%)
Married

64 (76.2)

Not married

20 (23.8)

Education, No. (%)
High school or less

26 (31.0)

College or more

34(67.8)

Missing

1 (1.2)

Employment, No. (%)

Author Manuscript

Work full-time or part-time

26 (31.0)

Retired

32 (38.1)

Other

25 (29.7)

Missing

1 (1.2)

Income, No. (%)
< 40K

31 (36.9)

≥ 40K

36 (42.9)

Prefer Not To Answer/Missing

17 (20.2)

Cancer type, No. (%)
Multiple Myeloma

58 (69.0)

Hodgkin lymphoma

8 (9.5)

Non-Hodgkin lymphoma
Amyloidosis

16 (19.1)
2 (2.4)

Author Manuscript

Time since transplant, days

M

349.98

SD

123.89

Functional Status, No. (%)
4

40 (47.6)
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Characteristic

Author Manuscript

3

35 (41.7)

2

6 (7.1)

1

1 (1.2)

Missing

2 (2.4)

Sleeping Medication, No. (%)
Yes

32 (38.1)

No

51 (60.7)

Missing

1 (1.2)

Note. SD = standard deviation.

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
0.09
−0.12

Diagnosis

Time since transplant

0.09
−0.18

0.25*
0.32**

FCRI Severity

FCRI Impairment

Bone Marrow Transplant. Author manuscript; available in PMC 2018 June 21.
−0.13
−0.04

0.67***
0.28*

GSES

SHI

0.07

0.21

0.18

0.23*

0.13

−0.02

−0.10

−0.08

0.07

0.02

0.11

−0.04

−0.09

−0.04

−0.09

−0.25*
−0.18

0.03
−0.06

−0.01

−0.06

−0.05

−0.11

WASO

−0.17

−0.06

0.08

−0.06

0.17

0.14

0.24*

0.03

0.14

0.03

0.05

0.10

0.07

TST

ISI = Insomnia Severity Index, SE = Sleep Efficiency, SOL = Sleep Onset Latency, WASO = Wake After Sleep Onset, TST = Total Sleep Time, IES = Impact of Events Scale, FCRI = Fear of Cancer
Recurrence Inventory, DBAS = Dysfunctional Beliefs and Attitudes about Sleep, GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index.

p < .001. Categorical variables were dichotomized and run as correlations.

***

p < .01,

p < .05,

**

*

Note. Table depicts r coefficients. Significant coefficients are bolded and marked with asterisks,

−0.01

0.54***

DBAS

Cognitive and Behavioral Risk Factors

0.17

0.25*

0.17

0.16

0.17

0.08

0.13

−0.30**

−0.02

0.03

0.22*

SOL

0.07

SE

IES Intrusion

Cancer-Specific Risk Factors

0.01
−0.10

−0.03

Married

Age

0.15

Education

0.11

Gender

Ethnicity

Demographic and Clinical Risk Factors

ISI total score

Relationships Between Demographic and Clinical Risk Factors, Cancer-Specific Risk Factors, Cognitive and Behavioral Risk Factors, and Subjective and
Objective Sleep Disturbance

Author Manuscript
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Table 3

Author Manuscript

Multivariable Hierarchical Regression Models with Subjective Sleep Disruption
R2

Risk Factors

Cancer-Specific Risk Factors

β

p

0.08

-

-

IES Intrusion

-

0.12

.36

FCRI Severity

-

0.05

.74

FCRI Impairment

-

0.25

.05

With Cognitive and Behavioral Factors

Author Manuscript

0.37

-

-

IES Intrusion

-

0.05

.61

FCRI Severity

-

−0.16

.18

FCRI Impairment

-

0.10

.29

DBAS

-

0.18

.11

GSES

-

0.55

< .001

SHI

-

0.04

.69

Note: IES = Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional Beliefs and Attitudes about Sleep,
GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index.

Author Manuscript
Author Manuscript
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Table 4

Author Manuscript

Multivariable Hierarchical Regression Models with Sleep Onset Latency
R2

Risk Factors

Demographic & Clinical Risk Factors

β

p

0.12

-

-

Age

-

−0.22

.04

Ethnicity

-

−0.27

.01

0.21

-

-

Age

-

−0.20

.05

Ethnicity

-

−0.26

.01

IES Intrusion

-

−0.20

.12

FCRI Severity

-

0.16

.26

FCRI Impairment

-

0.17

.16

With Cancer-Specific Risk Factors

Author Manuscript

With Cognitive and Behavioral Factors

0.23

-

-

Age

-

−0.20

.07

Ethnicity

-

−0.28

.008

IES Intrusion

-

−0.21

.10

FCRI Severity

-

0.11

.46

FCRI Impairment

-

0.14

.28

DBAS

-

0.08

.56

GSES

-

0.13

.41

SHI

-

−0.06

.62

Note: SOL = Sleep Onset Latency, IES = Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional Beliefs and
Attitudes about Sleep, GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index.
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Author Manuscript
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